Applications

1621 – Amendment to MBS Item 73344 for c-ROS proto-oncogene 1 fluorescence in situ hybridisation testing to identify ROS1, to determine patient eligibility for entrectinib under the Pharmaceutical Benefits Scheme

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

Amendment to MBS item.

Service or technology in this application

The proposed service is testing of the ROS1 gene rearrangement by fluorescence in situ hybridisation (FISH) to determine eligibility to access entrectinib under the PBS.

This submission requests a minor amendment to MBS item 73344 be made allowing its use to determine eligibility to access crizotinib or entrectinib under the PBS.

Type: Investigative

Medical condition this application addresses

Non-small cell lung cancer.

Application documents

Public summary document

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: N/A
  • ESC meeting: N/A
  • MSAC meeting: 3 April 2020